Data_Sheet_1_Meningitic Escherichia coli-Induced Interleukin-17A Facilitates Blood–Brain Barrier Disruption via Inhibiting Proteinase 3/Protease-Activated Receptor 2 Axis.docx
Bacterial meningitis is a life-threatening infectious disease with high morbidity and mortality worldwide, among which meningitic Escherichia coli is a common Gram-negative pathogenic bacterium causing meningitis. It can penetrate the blood–brain barrier (BBB), invoke local inflammatory responses and consequently disrupt the integrity of the BBB. Interleukin-17A (IL-17A) is recognized as a pro-inflammatory cytokine that is released during meningitic E. coli infection. It has been reported that IL-17A is involved in several pathological tissue injuries. However, the function of IL-17A in BBB breakdown remains rarely discussed. Here, our study found that E. coli-induced IL-17A led to the degradation of tight junction proteins (TJs) and adherens junction proteins (AJs) in human brain microvascular endothelial cells (hBMECs) through inhibiting protease proteinase 3 (PRTN3)/protease-activated receptor 2 (PAR-2) axis, thus increasing the permeability of BBB. In summary, this study uncovered the involvement of IL-17A in regulating BBB integrity and proposed a novel regulatory mechanism, which could be potential therapeutic targets of E. coli meningitis.
History
References
- https://doi.org//10.1016/j.biopha.2021.112184
- https://doi.org//10.3390/cells10061400
- https://doi.org//10.1097/00008480-199802000-00004
- https://doi.org//10.1016/j.neuroscience.2008.06.025
- https://doi.org//10.1016/j.ajpath.2014.01.023
- https://doi.org//10.1016/j.devcel.2009.01.004
- https://doi.org//10.1172/JCI80792
- https://doi.org//10.1038/s41423-020-00582-8
- https://doi.org//10.1159/000320177
- https://doi.org//10.1111/cmi.12099
- https://doi.org//10.1186/s13041-021-00826-2
- https://doi.org//10.1155/2019/8474523
- https://doi.org//10.1124/pr.57.2.4
- https://doi.org//10.1097/00001432-200406000-00009
- https://doi.org//10.12688/f1000research.8533.1
- https://doi.org//10.1007/978-1-4757-4580-1_3
- https://doi.org//10.1038/nrn1103
- https://doi.org//10.7150/thno.11685
- https://doi.org//10.1002/hep.23055
- https://doi.org//10.1161/ATVBAHA.112.300474
- https://doi.org//10.1016/s0891-5520(05)70093-3
- https://doi.org//10.1007/s10571-020-00985-1
- https://doi.org//10.1186/s12864-015-1890-9
- https://doi.org//10.3390/nu12103095
- https://doi.org//10.4049/jimmunol.1401894
- https://doi.org//10.1128/CMR.00008-11
- https://doi.org//10.2174/187152809787582543
- https://doi.org//10.1186/1743-8977-10-62
- https://doi.org//10.1172/JCI36759
- https://doi.org//10.1038/ni.3726
- https://doi.org//10.3171/foc.2007.22.5.5
- https://doi.org//10.1016/j.jstrokecerebrovasdis.2018.06.042
- https://doi.org//10.1002/med.20064
- https://doi.org//10.1007/s12035-020-02214-8
- https://doi.org//10.1006/mpat.2000.0406
- https://doi.org//10.1038/nri.2017.50
- https://doi.org//10.3109/09687688.2014.937468
- https://doi.org//10.1161/ATVBAHA.115.307080
- https://doi.org//10.2353/ajpath.2008.070690
- https://doi.org//10.1146/annurev-biochem-061516-044859
- https://doi.org//10.1038/ni.3742
- https://doi.org//10.3389/fimmu.2018.01148
- https://doi.org//10.3233/JAD-150759
- https://doi.org//10.3390/ijms22126343
- https://doi.org//10.1111/cns.13626
- https://doi.org//10.1186/s12974-021-02165-4
- https://doi.org//10.1186/s12974-019-1497-1
- https://doi.org//10.18632/oncotarget.11696
- https://doi.org//10.1016/j.neuron.2008.01.003
CC BY 4.0